5-Acetylpyrimidine-2-carbonitrile

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Acetylpyrimidine-2-carbonitrile
• 英文别名: 5-acetylpyrimidine-2-carbonitrile
• 化学式: C₇H₅N₃O
• 分子量: 147.13
• InChiKey: AICPGQYEPJTKOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Non-selective kinase inhibitors
  申请人：Pulmokine, Inc.

  公开号：US10246438B2

  公开（公告）日：2019-04-02

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

  本文公开了用于预防和治疗与受体酪氨酸激酶（RTK）活性异常相关的增殖性疾病的化合物、组合物和方法。本文所述的治疗适应症更具体地涉及对与血管和肺部疾病相关的 RTK 的非选择性抑制。
• NON-SELECTIVE KINASE INHIBITORS
  申请人：ZIAMAN Lawrence

  公开号：US20150353527A1

  公开（公告）日：2015-12-10

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
• SPRAY DRY FORMULATIONS
  申请人：ZISMAN Lawrence S.

  公开号：US20160235742A1

  公开（公告）日：2016-08-18

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
• US9815815B2
  申请人：——

  公开号：US9815815B2

  公开（公告）日：2017-11-14
• [EN] THERAPEUTIC INDICATIONS OF KINASE INHIBITORS<br/>[FR] INDICATIONS THÉRAPEUTIQUES D'INHIBITEURS DE KINASE
  申请人：ZISMAN LAWRENCE S

  公开号：WO2014110198A2

  公开（公告）日：2014-07-17

  Disclosed herein are compounds, compositions, and methods for preventing and treating diseases associated with protein kinase activity. The therapeutic indications described herein relate to receptor tyrosine kinase (RTK) inhibition for the treatment or prevention of vascular conditions and proliferative disorders. The disclosure also relates to irreversible RTK inhibitors.